# Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19

> **NCT04252274** · PHASE3 · UNKNOWN · sponsor: **Shanghai Public Health Clinical Center** · enrollment: 30 (estimated)

## Conditions studied

- Pneumonia, Pneumocystis
- Coronavirus

## Interventions

- **DRUG:** Darunavir and Cobicistat

## Key facts

- **NCT ID:** NCT04252274
- **Lead sponsor:** Shanghai Public Health Clinical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-30
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252274, "Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04252274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*